|
|
 |
|
Viewing report
|
|
|
|
Non-Hodgkin's Lymphoma (NHL) - Drug Pipeline Analysis and Market Forecasts to 2015
GlobalData, Jan 2010, Pages: 84
Non-Hodgkin’s Lymphoma (NHL) - Drug Pipeline Analysis and Market Forecasts to 2015
Summary
GlobalData, the industry analysis specialist, has released a new report on the Pharmaceutical and Healthcare industry, “Non-Hodgkin's Lymphoma - Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global NHL market. The report identifies the key trends shaping and driving the global NHL market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NHL sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Our team of industry experts.
Scope
The scope of the report includes:
- Annualized global Non-Hodgkin's Lymphoma (NHL) market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global NHL market. Key market players covered include Genentech, Inc., GSK, Eli Lilly and Company, Pfizer Inc/ Wyeth, Novartis AG, and Biogen Idec.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NHL.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NHL disease market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global NHL disease market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global NHL disease market landscape? - Identify, understand and capitalize.
Customers who bought this item also bought
Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report
Lymphoma Therapeutics - Global Strategic Business Report
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
New Approaches to the Treatment of Non-Hodgkin's Lymphoma
Lymphoma Drug Development Strategies at Work - Define Your Competition
Non-Hodgkin's Lymphoma (NHL) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Non-Hodgkin Lymphoma Global Clinical Trials Review, H2, 2011
Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Stakeholder Insight: Non-Hodgkin's Lymphomas Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)
|
|
|
|
